Streamline Health® Reports Fourth Quarter and Fiscal Year 2019 Financial Results

  • Fourth Quarter 2019 revenue $4.8 million; Net Loss ($2.4 million); Adjusted EBITDA $479,000
  • Fiscal Year 2019 revenue $20.7 million; Net Loss ($2.9 million); Adjusted EBITDA $3.1 million

Atlanta, GA, April 22, 2020 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of integrated solutions, technology-enabled services and analytics to support revenue cycle optimization for healthcare enterprises, today announced financial results for the fourth quarter and fiscal year 2019 which ended January 31, 2020.

Total revenues for the fourth quarter of fiscal year 2019 were $4.8 million, compared to $5.5 million in the prior year period. Recurring revenue comprised 84% of fourth quarter 2019 revenue. Fiscal year 2019 revenue was $20.7 million, compared to $22.4M in fiscal year 2018.

Net loss for the fourth quarter of fiscal year 2019 was ($2.4 million), compared to a loss of ($3.1 million) during fourth quarter 2018. Fiscal year 2019 net loss was ($2.9 million) compared to a loss of ($5.9 million) during fiscal year 2018. The net loss for fiscal year 2019 included a number of non-recurring and transaction costs incurred by the Company to affect the sale of its enterprise content management (“ECM”) business, which was closed and funded on February 24, 2020.

Adjusted EBITDA for the fourth quarter of fiscal year 2019 was $479,000, compared to $1.1 million in the fourth quarter of fiscal year 2018. Total Adjusted EBITDA for fiscal year 2019 was $3.1 million, up 8.4% compared to $2.9 million in fiscal year 2018.

“I believe fiscal year 2019 was a transformational one for our Company. In just the second half of the year, we fundamentally transformed our Company for future growth. It required numerous strategic moves such as raising capital to retire the Company’s preferred shares and changing our banking relationship,” stated Tee Green, President and Chief Executive Officer, Streamline Health. “All of this was necessary to sell our legacy ECM business and thereby remove the most significant headwind to improving revenue growth while providing an influx of capital so that we could remove our bank debt and invest in our flagship eValuator™ technology.

“As we look ahead to 2020 and beyond, Streamline Health is a smaller, more nimble, SaaS- based technology company focused on helping healthcare provider customers improve efficiency in the middle of their revenue cycle.

“While the novel Coronavirus has changed the healthcare landscape, we believe that its effects will generate greater demand for our solutions and services once hospitals return to more normal operations. Our customers need every dollar of revenue since postponed elective procedures provide better margins. Our eValuator technology will help them better capture the full reimbursement they deserve for the care they provide.”

Highlights from the fourth quarter ended January 31, 2020 included

  • Revenue for the fourth quarter 2019 was $4.8 million
  • Net loss for the fourth quarter 2019 was ($2.4 million)
  • Adjusted EBITDA for the fourth quarter 2019 was $479,000
  • Bookings for the fourth quarter 2019 were $1.0 million

Highlights from the year ended January 31, 2020 included

  • Revenue for fiscal 2019 was $20.7 million
  • Net loss for fiscal 2019 was ($2.9 million)
  • Adjusted EBITDA for fiscal 2019 was $3.1 million
  • Bookings for fiscal 2019 were $8.9 million

Conference Call

The Company will conduct a conference call to review the results on Thursday, April 23, 2020 at 9:00 AM ET. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-269-7756.

A replay of the conference call will be available from Thursday, April 23, 2020 at 12:00 PM ET to Thursday, April 30, 2020 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13701674. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline Health website,

Non-GAAP Financial Measures

Streamline Health reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP"). Streamline Health's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health's management believes that this measure provides useful supplemental information regarding the performance of Streamline Health's business operations.

Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table illustrating this measure and a reconciliation to comparable GAAP measures is included in this press release.

About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge­ – providing actionable insights that support revenue cycle optimization for healthcare enterprises. We deliver integrated solutions, services and analytics that enable providers to drive reimbursement in a value-based world. We share a common calling and commitment to advance the quality of life and the quality of healthcare—for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company's growth prospects, estimates of backlog, industry trends and market growth, results of investments in sales and marketing, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company's solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, and the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Randy Salisbury
SVP, Chief Sales & Marketing Officer
(404) 229-4242




  Three Months Ended  Twelve Months Ended 
  January 31,  January 31, 
  2020  2019  2020  2019 
Systems sales $173,000  $645,000  $1,219,000  $2,472,000 
Professional services  186,000   250,000   1,801,000   1,336,000 
Audit Services  446,000   277,000   1,712,000   1,118,000 
Maintenance and support  2,772,000   3,009,000   11,309,000   12,586,000 
Software as a service  1,228,000   1,284,000   4,702,000   4,853,000 
Total revenues  4,805,000   5,465,000   20,743,000   22,365,000 
Operating expenses:                
Cost of systems sales  631,000   179,000   1,022,000   942,000 
Cost of professional services  487,000   578,000   2,103,000   2,657,000 
Cost of audit services  306,000   356,000   1,255,000   1,373,000 
Cost of maintenance and support  410,000   453,000   1,685,000   2,173,000 
Cost of software as a service  479,000   187,000   1,415,000   992,000 
Selling, general and administrative  2,066,000   2,394,000   9,811,000   10,554,000 
Research and development  1,170,000   959,000   3,555,000   4,261,000 
Executive Transition Costs  168,000   -   789,000   - 
Restructuring Charges  388,000   -   388,000   - 
Transaction Costs  861,000   -   861,000   - 
Impairment of Long-lived Assets      3,681,000   -   3,681,000 
Loss on exit of operating lease  -   (334,000)  -   1,034,000 
Total operating expenses  6,966,000   8,453,000   22,884,000   27,667,000 
Operating loss  (2,161,000)  (2,988,000)  (2,141,000)  (5,302,000)
Other expense:                
Interest expense  (70,000)  (52,000)  (309,000)  (384,000)
Miscellaneous expense  (167,000)  (61,000)  (391,000)  (179,000)
Loss before income taxes  (2,398,000)  (3,101,000)  (2,841,000)  (5,865,000)
Income tax benefit (expense)  (6,000)  5,000   (22,000)  - 
Net Loss $(2,404,000) $(3,096,000) $(2,863,000) $(5,865,000)
Add: Redemption of Series A Preferred Stock  4,894,000   -   4,894,000   - 
Net income (loss) attributable to common shareholders $2,490,000  $(3,096,000) $2,031,000  $(5,865,000)
Net income (loss) per common share – basic $0.08  $(0.16) $0.09  $(0.30)
Weighted average number of common shares – basic  29,653,550   19,676,686   22,739,679   19,540,980 
Net loss per common share - diluted $(0.08) $(0.16) $(0.13) $(0.30)
Weighted average number of common shares – diluted  29,653,550   19,676,686   22,739,679   19,540,980 




  January 31, 2020  January 31, 2019 
Current assets:        
Cash and cash equivalents $1,649,000  $2,376,000 
Accounts receivable, net  3,166,000   2,933,000 
Contract receivables  820,000   1,263,000 
Prepaid hardware and other current assets  919,000   1,048,000 
Total current assets  6,554,000   7,620,000 
Non-current assets:        
Property and equipment, net  152,000   237,000 
Contract Receivables, less current portion  -   407,000 
Capitalized software development costs  7,598,000   5,698,000 
Intangible assets, net  1,115,000   1,669,000 
Goodwill  15,537,000   15,537,000 
Other non-current assets  695,000   572,000 
Total non-current assets  25,097,000   24,120,000 
  $31,651,000  $31,740,000 
Liabilities and Stockholders’ Equity        
Current liabilities:        
Accounts payable $1,270,000  $1,280,000 
Accrued compensation  866,000   789,000 
Accrued other expenses  671,000   1,025,000 
Current portion of term loan  3,825,000   597,000 
Deferred revenues  7,990,000   8,338,000 
Royalty Liability  969,000   - 
Other  -   94,000 
Total current liabilities  15,591,000   12,123,000 
Non-current liabilities:        
Term loan, net of current portion  -   3,351,000 
Royalty liability  -   905,000 
Deferred revenues, less current portion  55,000   432,000 
Other liabilities  -   41,000 
Total non-current liabilities  55,000   4,729,000 
Total liabilities  15,646,000   16,852,000 
Series A 0% Convertible Redeemable Preferred Stock  -   8,686,000 
Stockholders’ equity  16,005,000   6,202,000 
  $31,651,000  $31,740,000 




  Fiscal Year 
  2019  2018 
Cash flows from operating activities:        
Net loss $(2,863,000) $(5,865,000)
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation  137,000   450,000 
Amortization of capitalized software development costs  1,458,000   1,160,000 
Amortization of intangible assets  554,000   937,000 
Amortization of other deferred costs  480,000   415,000 
Valuation adjustments  64,000   126,000 
Loss on early extinguishment of debt  150,000   - 
Impairment of long-lived assets  -   3,681,000 
Loss on exit of operating lease  -   1,034,000 
Loss on disposal of fixed assets  -   7,000 
Share-based compensation expense  934,000   629,000 
Provision for accounts receivable  (201,000)  13,000 
Changes in assets and liabilities  (721,000)  (1,190,000)
Net cash (used in) provided by operating activities  (8,000)  1,397,000 
Cash flows used in investing activities:        
Purchases of property and equipment  (52,000)  (21,000)
Proceeds from sales of property and equipment  -   21,000 
Capitalization of software development costs  (3,358,000)  (3,003,000)
Net cash used in investing activities  (3,410,000)  (3,003,000)
Cash flows from financing activities:        
Proceeds from issuance of common stock  9,663,000   - 
Payments for costs directly attributable to the issuance of common stock  (711,000)  - 
Proceeds from term loan  4,000,000   - 
Principal payments on term loan  (4,030,000)  (597,000)
Proceeds from exercise of stock options and stock purchase plan  8,000   44,000 
Redemption of Series A Convertible Preferred Stock  (5,791,000)  - 
Fees paid for redemption of Series A Convertible Preferred Stock  (22,000)  - 
Payments related to settlement of employee shared-based awards  (99,000)  (62,000)
Payment of deferred financing costs  (325,000)  (23,000)
Other  (2,000)    
Net cash provided by (used in) financing activities  2,691,000   (638,000)
Net decrease in cash and cash equivalents  (727,000)  (2,244,000)
Cash and cash equivalents at beginning of year  2,376,000   4,620,000 
Cash and cash equivalents at end of year  1,649,000   2,376,000 


New Bookings


Table B

  January 31, 2020 
  Three Months Ended  Twelve Months Ended 
Systems Sales $92,000  $1,209,000 
Professional Services  178,000   1,666,000 
Audit Services  9,000   288,000 
Maintenance and Support  28,000   1,679,000 
Software as a Service  698,000   4,004,000 
  $1,005,000  $8,846,000 
Total FY 2018 bookings $1,123,000  $8,221,000 
Total FY 2017 bookings $1,192,000  $4,756,000 

Reconciliation of Non-GAAP Financial Measures
Table C
This press release contains a non-GAAP financial measure under the rules of the U.S. Securities and Exchange Commission for Adjusted EBITDA. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget. Streamline Health’s management in its operating and financial decision-making uses non-GAAP financial measures because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, the Company believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a) understand and evaluate current operating performance and future prospects in the same manner as management does and (b) compare in a consistent manner the Company’s current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. The Company’s management compensates for these limitations by considering the Company’s financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release. Streamline Health defines “Adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, professional and advisory fees, and internal direct costs incurred to complete transactions.

Reconciliation of net loss to non-GAAP Adjusted EBITDA (in thousands):


  Three Months Ended,  Twelve Months Ended, 
  January 31, 2020  January 31, 2019  January 31, 2020  January 31, 2019 
Net loss $(2,404) $(3,095) $(2,863) $(5,865)
Interest expense  70   52   309   384 
Income tax benefit  6   (6)  22   - 
Depreciation  24   39   137   450 
Amortization of capitalized software development  814   265   1,458   1,160 
Amortization of intangible assets  130   232   554   937 
Amortization of other costs  87   52   237   346 
EBITDA  (1,273)  (2,461)  (146)  (2,588)
Share-based compensation expense  215   136   934   629 
Impairment of long-lived assets  -   3,681   -   3,681 
Loss on disposal of fixed assets  -   2   -   7 
Non-cash valuation adjustments  17   55   64   126 
Executive transition costs (1)  168   -   725   - 
Rationalization Charges  388   -   388   - 
Transaction costs  861   -   861   - 
Loss on early extinguishment of debt  -   -   150   - 
Loss on exit of operating lease  -   (334)      1,034 
Other non-recurring expenses  103   -   157   - 
Adjusted EBITDA $479  $1,079  $3,133  $2,889 
Adjusted EBITDA per diluted share:                
Net loss per common share – diluted $(0.08) $(0.16) $(0.13) $(0.30)
Adjusted EBITDA per adjusted diluted share (1) $0.02  $0.05  $0.12  $0.13 
Diluted weighted average shares  29,653,550   19,676,686   22,739,679   19,540,980 
Includable incremental shares — Ad EBITDA (2)  442,627   3,161,821   2,343,382   3,065,402 
Adjusted diluted shares (4)  30,096,176   22,838,507   25,083,061   22,606,382 

(1) Executive transition cost on the consolidated statement of operations includes $64,000 in stock compensation expense for fiscal 2019, which is included within Share-based compensation expense in the Adjusted EBITDA calculation above.

(2) Adjusted EBITDA as a percentage of GAAP net revenues.

(3) Adjusted EBITDA per adjusted diluted share for the Company’s common stock is computed using the more dilutive of the two-class method or the if-converted method.

(4) The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed.